<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758172</url>
  </required_header>
  <id_info>
    <org_study_id>2008-1001</org_study_id>
    <nct_id>NCT01758172</nct_id>
  </id_info>
  <brief_title>Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Comparison of Hemodynamic and Clinical Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      From postoperative patients having undergone pancreaticoduodenectomy;

        1. To compare the hemodynamic parameters from the patient administrated 5% HA and 6%
           Voluven

        2. To assess the efficacy of the treatment as regards the clinical outcomes and laboratory
           parameters of the patient

        3. To compare the safety of the 2 intravenous colloids in the patient population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>post-op 24hr</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume(ml) of colloid</measure>
    <time_frame>post-op 24hrs</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>albumin was administered to reach CVP up to 7mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6% hydroxyethyl starch 130/0.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% hydroxyethyl starch 130/0.4</intervention_name>
    <arm_group_label>6% hydroxyethyl starch 130/0.4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects should be meet inclusion criteria to participated into the study

               1. Age-from 18-75 years adult

               2. In the immediate post-operative period of pancreaticoduodenectomy

               3. Written informed consent and admitted ICU immediate post-operative patient

        Exclusion Criteria:

          -  Any patient meeting one or more of the following exclusion criteria may not be
             entered into the study.

               1. Refusal to participate in the study

               2. Evidence of pre-operative oliguria (Serum creatinine&gt;1.5mmol/dL)

               3. Known Severe congestive heart failure (NYHAIII,IV)

               4. Known severe respiratory diseases (PaO2/FiO2 &lt;200)

               5. Known coagulopathy (Platelet&lt;100k/mm3, aPTT&gt;70s, PT(INR)&gt;2.5)

               6. Known allergy to hydroxyethyl starch

               7. Known pregnancy or lactation

               8. Has participated in any other clinical trial within 3months

               9. Any contraindication to VoluvenÂ® or albumin according to their package
                  inserts.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Song-cheol Kim, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 1, 2013</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Song Cheol Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>postoperative patient</keyword>
  <keyword>colloid</keyword>
  <keyword>albumin</keyword>
  <keyword>hetastarch</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hetastarch</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
